Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) Research & Development (2022 - 2025)

Praxis Precision Medicines (PRAX) has 4 years of Research & Development data on record, last reported at $77.5 million in Q4 2025.

  • For Q4 2025, Research & Development rose 37.7% year-over-year to $77.5 million; the TTM value through Dec 2025 reached $267.1 million, up 75.26%, while the annual FY2025 figure was $267.1 million, 75.26% up from the prior year.
  • Research & Development reached $77.5 million in Q4 2025 per PRAX's latest filing, up from $65.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $77.5 million in Q4 2025 and bottomed at $17.3 million in Q3 2023.
  • Average Research & Development over 4 years is $41.3 million, with a median of $36.2 million recorded in 2022.
  • Peak YoY movement for Research & Development: crashed 51.56% in 2023, then skyrocketed 206.11% in 2024.
  • A 4-year view of Research & Development shows it stood at $28.3 million in 2022, then tumbled by 35.09% to $18.4 million in 2023, then surged by 206.11% to $56.3 million in 2024, then surged by 37.7% to $77.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $77.5 million in Q4 2025, $65.8 million in Q3 2025, and $63.0 million in Q2 2025.